GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international
Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Dialogue’s Triage Support Technology Earns CE Mark
Artificial intelligence is “an important asset to reduce human bias when medical professionals triage patients in emergency rooms,” the company said.
Woodcock to Congress: U.S. Must Revamp Manufacturing to Spur API Production
Only 28 percent of facilities making APIs for the U.S. market are domestic.
FDAnews Drug Daily Bulletin
GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
June 6, 2006
